These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 3249619)
21. [Evaluation of the results of the treatment of patients with subacute sclerosing panencephalitis with TFX-Polfa]. Vainiene M; Sobczyk W Neurol Neurochir Pol; 1985; 19(4):286-90. PubMed ID: 2419779 [TBL] [Abstract][Full Text] [Related]
22. Influence of thymus factor (TFX "Polfa") on the ability of granulocytes to absorb neutral latex particles and Staphylococcus aureus in patients treated for long-time periods with corticosteroids. Matusiewicz R; Czajkowski M; Kowalczyk M Mater Med Pol; 1988; 20(2):132-4. PubMed ID: 3221731 [No Abstract] [Full Text] [Related]
23. [Calf thymus extract (TFX-Polfa) in the treatment of pollinosis. Clinical trials by the double-blind method using a placebo]. Kowalski ML; Kuna P; Grzegorczyk J; Rozniecki J Pol Tyg Lek; 1987 Jun; 42(24):739-42. PubMed ID: 3313315 [No Abstract] [Full Text] [Related]
24. [Results of one-year treatment of multiple sclerosis with azathioprine compared with the therapy using small doses of Encorton]. Wender M; Tokarz-Kupczyk E; Mularek O; Sniatała-Kamasa M Neurol Neurochir Pol; 1991; 25(3):307-13. PubMed ID: 1961376 [TBL] [Abstract][Full Text] [Related]
25. [Myasthenic syndrome after parenteral administration of thymus extracts]. Vesentini G; Morelli B; Figà-Talamanca L; Carratelli D Riv Neurobiol; 1978; 24(1-2):109-114. PubMed ID: 575431 [No Abstract] [Full Text] [Related]
26. [Clinical trial of immunoregulation using the TFX Polfa preparation in non-Hodgkin's lymphoma]. Górski J; Kicińska M; Gawrecka G Przegl Lek; 1988; 45(7):555-8. PubMed ID: 3070639 [No Abstract] [Full Text] [Related]
27. [Comparison of oral administration and intramuscular injection of thymus preparations on the leukopoiesis test in rats and some of the preventive possibilities emerging from the results]. von Ardenne M; Reitnauer PG Z Alternsforsch; 1985; 40(4):225-34. PubMed ID: 4049925 [TBL] [Abstract][Full Text] [Related]
28. TFX-polfa in the treatment of transplantable Morris 5123 hepatoma in buffalo rats. Rzeszutko W Patol Pol; 1992; 43(2):58-62. PubMed ID: 1296178 [TBL] [Abstract][Full Text] [Related]
30. The effect of thymus factor X (TFX Polfa) on the clinical course of human trichinellosis. Kociecka W; Skrzypińska K; Machowska L Wiad Parazytol; 1989; 35(5):423-33. PubMed ID: 2815766 [No Abstract] [Full Text] [Related]
31. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a. Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303 [TBL] [Abstract][Full Text] [Related]
32. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients. Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872 [TBL] [Abstract][Full Text] [Related]
33. [Combined effect of the allergen and thymus extract (TFX) in the desensitization of patients with hay fever]. Turowski G; Dynowska D; Sanokowska E; Kotlinowska T Pol Tyg Lek; 1987 Jun; 42(24):745-6. PubMed ID: 3671177 [No Abstract] [Full Text] [Related]
34. [Therapeutic effectiveness of the immuno stimulating extract of the calf thymus (TFX-Polfa) in cases of acute dermatomyositis]. Stasiak A; Dudkiéwicz H; Dabrowski M; Dabrowska B; Wasowska B; Brzosko W Pol Tyg Lek; 1983 Mar; 38(13):389-92. PubMed ID: 6605525 [No Abstract] [Full Text] [Related]
35. Pharmacological properties of the extract of thymus gland (Thymomodulin-TFX) and its effect on reproduction. Kosmala M; Oledzka K; Kaszczyńska M; Lewandowski K; Przemyk B; Filczewski M; Sliwoska M Acta Pol Pharm; 1993; 50(6):447-52. PubMed ID: 8067258 [TBL] [Abstract][Full Text] [Related]
36. [Evaluation of the results of treating progressive multiple sclerosis with cyclophosphamide]. Wajgt A; Szyrocka-Szwed K; Gadomska B; Szczechowski L Neurol Neurochir Pol; 1988; 22(6):518-23. PubMed ID: 3077433 [TBL] [Abstract][Full Text] [Related]
37. [Clinical trial of treatment with the preparation TFX "Polfa" of 4 patients with acquired immunologic deficiency syndromes]. Romański B; Montowska L; Zbikowska-Götz M; Staszyńska M Pol Tyg Lek; 1985 Oct 7-14; 40(40-41):1139-42. PubMed ID: 3911181 [No Abstract] [Full Text] [Related]
38. The effect of TFX (Polfa) on mouse fibroblasts and macrophages in carcinogenicity assays. Duś D; Radzikowski C Arch Immunol Ther Exp (Warsz); 1983; 31(5):731-7. PubMed ID: 6675574 [TBL] [Abstract][Full Text] [Related]
39. [Effect of treatment with Encorton (Polfa), Solu-Medrol and Encorton and Cyclophosphamide and Encorton on the production of immunoglobulin G in the central nervous system in multiple sclerosis]. Ochudło S Wiad Lek; 1989 Dec; 41(23):1579-83. PubMed ID: 2669352 [No Abstract] [Full Text] [Related]
40. [Stimulation of phagocyte activity by Thym-Uvocal in chronic skin infections]. Hagedorn M Onkologie; 1989 Jun; 12 Suppl 3():39-40, 42. PubMed ID: 2691944 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]